GET DAILY SIGNALSWhy Is Electromed (ELMD) Stock Up +0.24% Today?
Key Takeaways
- ELMD shares were up about 0.24% to $25.02 in early trading, steadying after the prior session's 8.17% post-earnings slide.
- Primary catalyst: digestion of fiscal first-quarter 2027 results reported after the close on Nov. 10 — an earnings beat offset by a revenue miss and decelerating top-line growth.
- Secondary drivers: CEO Jim Cunniff's planned April 2027 retirement (with no successor yet named) and steep declines in distributor and hospital revenue.
- Broader context: the small-cap medical-device stock remains in a downtrend, down roughly 34% over the past three months.
- Traders are watching support near the mid-$24 area, credit-facility renewal, and clarity on the CEO transition.
- For deeper data on valuation and outlook, explore Electromed's Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are positioned across the market via Tickeron's Trending AI Robots.
Opening Summary
Electromed, Inc. (ELMD), a New Prague, Minnesota-based maker of the SmartVest Airway Clearance System used by patients with compromised pulmonary function, was modestly higher in Thursday's session. The stock traded at $25.02, up 0.24% from its prior close of $24.96, as investors digested the company's fiscal 2027 first-quarter results. The move marks a pause in the selling pressure that drove shares down 8.17% in the previous session, when the market reacted to a mixed quarterly report and news of a leadership transition.
Earnings Results and Guidance
The primary catalyst behind the recent volatility in ELMD is its fiscal first-quarter 2027 report, released after the market close on Nov. 10. Net revenue rose 10.6% year over year to $18.7 million, while home care revenue — which represents about 94% of total sales — climbed 17.6% to $17.5 million. Gross margin expanded to 80.0% from 78.1% a year earlier, and operating income jumped 30.7% to $3.5 million. Diluted earnings per share of $0.32 beat consensus estimates.
Yet the market focused on the weaker elements of the report. Revenue came in slightly below the consensus estimate, and headline growth continued to decelerate. Non-home care revenue fell 41% to $1.2 million, driven by a 56% drop in distributor revenue and a 32% decline in hospital revenue as distributors worked through elevated inventory. Management signaled that a rebound in those channels is not expected until early calendar 2027. The tension between margin-driven profit growth and a slowing top line has defined the recent price action.
Leadership Transition Adds Uncertainty
A second overhang is governance. The company confirmed that CEO Jim Cunniff plans to retire in April 2027, with no successor yet announced. Leadership transitions at small-cap companies frequently weigh on sentiment, particularly when they coincide with a shift in the revenue mix. The company is also approaching the expiration of its credit facility, a detail that adds near-term financial-planning considerations even though Electromed carries no debt and ended the quarter with $15.9 million in cash.
Market Context and Trading Activity
The move in ELMD should be viewed against a backdrop of persistent technical weakness. Shares have fallen roughly 34% over the past three months and remain well below the levels reached after the August earnings report. The prior session's decline saw volume expand above the stock's recent daily average, reflecting active repositioning after the earnings announcement. Thursday's modest recovery suggests the stock is stabilizing around the mid-$24 to $25 zone, with the prior session's intraday low near $24.50 serving as a near-term reference level. The rebound has been gradual rather than accompanied by a sharp surge in volume, indicating that buyers are stepping in cautiously.
What Comes Next for ELMD
Looking ahead, investors will monitor several factors for ELMD. The company's next quarterly report and any updates on fiscal 2027 guidance will be closely watched, as will progress in rebuilding distributor and hospital channel revenue. The CEO succession process and renewal of the credit facility represent key governance and capital-structure milestones. Analysts broadly maintain a constructive view of the company's fundamentals, citing its debt-free balance sheet and direct-to-patient model, but technical weakness and slowing headline growth remain the central risks. Market participants will be watching whether the stock can hold support and whether renewed volume confirms a more durable recovery.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of automated approaches to explore. Traders looking to track momentum or identify new opportunities may find it useful to review the currently trending strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ELMD sees its Stochastic Oscillator climbs out of oversold territory
On November 04, 2026, the Stochastic Oscillator for ELMD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 72 instances where the indicator left the oversold zone. In 52 of the 72 cases the stock moved higher in the following days. This puts the odds of a move higher at over 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ELMD's RSI Oscillator exited the oversold zone, 14 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELMD advanced for three days, in 184 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ELMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELMD as a result. In 63 of 118 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for ELMD turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 22 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
ELMD moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ELMD moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
The Aroon Indicator for ELMD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ELMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.211) is normal, around the industry mean (4.142). P/E Ratio (19.832) is within average values for comparable stocks, (3.291). ELMD's Projected Growth (PEG Ratio) (103.010) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.080) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of airway clearance products
Industry MedicalNursingServices
Advertisement